Trastuzumab-QYYP(Pfizer Inc.)

DALLAS--(BUSINESS WIRE)-- Lantern Pharma, Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo M.D., M.Sc., MBA, as Vice President of Clinical Development, and several additional team members. The expansion of the clinical development team will continue to advance the Harmonic™ trial, a Phase 2 trial for never smokers with NSCLC, as well as the upcoming first-in-human Phase 1 clinical trials for Lantern’s drug candidates LP-184 and LP-284, which are both anticipated to launch in mid-2023. “We are looking forward to the many contributions that Dr. Ewesuedo and our expanded clinical development team will bring to Lantern and our clinical programs,” said Panna Sharma, Lantern’s President and CEO. “They are joining Lantern at a pivotal period in our company’s growth as we advance our drug candidates into and through clinical trials. I am confident in the decades of proven experience of our new team members and their ability to progress Lantern’s drug candidates to improve the lives of cancer patients,” continued Sharma. Dr. Ewesuedo has over 20 years of experience in preclinical, early, and late phase drug development including roles in clinical development leadership at AstraZeneca, Genzyme/Sanofi, Pfizer, Tesaro/GlaxoSmithKline, and Kymera. His leadership and experience have led to the development of several drugs including the successful filings for Trazimera™ (trastuzumab), Nyvepria™ (pegfilgrastim), and Zirabev™ (bevacizumab), while he was at Pfizer. In addition to his industry experience, he also served as a clinical research faculty member at The Ohio State University from 2000-2005. He holds an M.D. from the University of Ibadan, College of Medicine, Ibadan, Nigeria, a M.Sc. in Pharmacology from Ahmadu Bello University, Zaria, Nigeria, and an MBA from St. Mary’s University, Greehey Business School, San Antonio, TX. Dr. Ewesuedo completed his subspecialties training in Hematology and Pediatric Oncology, and Clinical Pharmacology and Pharmacogenomics, at the University of Chicago. Lantern has also recently appointed Ernest Kitt as Head of Clinical Operations. Mr. Kitt has over 20 years of experience in oncology drug development and clinical operations with proven success in bringing drugs to market. He has held clinical oncology leadership positions at companies including Amgen/Onyx, Aptose, and Biosplice. Other additions to the clinical development team include Annum Zhara as a Senior Clinical Trial Project Manager and Brianna MacCrory as a Clinical Trial Navigator. About Lantern Pharma: Lantern Pharma (NASDAQ: LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR® AI and machine learning platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. By targeting drugs to patients whose genomic pro them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes. Forward-looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 10, 2022. You may access our Annual Report on Form 10-K for the year ended December 31, 2021 under the investor SEC filings tab of our website at or on the SEC's website at . Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

Emerging economies across the Asia-Pacific and Africa are expected to emerge as key investment destinations for key giants Fact.MR, Rockville MD: Fact.MR’s generic injectables market report forecasts a relatively stable outlook for 2021, majorly fueled by accelerating regulatory approvals to initiate clinical trials for developing possible drug candidates to eradicate the novel coronavirus pandemic. Recessionary downturns were avoided significantly through 2020, as candidates were endowed with priority approval status by regulatory authorities. Future growth prospects are heavily reliant on accrued historical gains arising out of high import dependence from key manufacturing hubs. India is anticipated to reap the maximum benefits, as generic drugs contribute greater than 70% of the total pharmaceutical industry revenue. As of now, a total of 19 active pharmaceutical ingredient (API) applications have been approved under the Production Linked Incentive (PLI) Scheme to promote domestic manufacturing of Key Starting Materials (KSMs) at a cost of US$ 636 million. According to Fact.MR’s projections, the market is expected to cross US$ 1 billion by the middle of this decade, a significant chunk of which is anticipated to be yielded from accelerated development of anti-retroviral drugs. In November 2020, for instance, a coalition of 18 pharmaceutical companies across India, Bangladesh, China and South Africa- the four key emerging economies- specializing in generic drugs are expected to bolster drug development prospects for the SARS CoV2. The collaboration includes Sun Pharma, Lupin, Heterco, Natco, Strides Shasun, Aurobindo and Zydus Cadila. “Prominent generic injectables manufacturers are taking advantage of increasing government approvals for biosimilar candidates to accelerate treatment of several chronic and infectious conditions, prompting a flurry of clinical trials and product launches, providing stimulus to market growth,” says the Fact.MR analyst. Request a report sample with 170 pages to gain comprehensive insights at Key Takeaways from Fact.MR’s Generic Injectables Study Large molecular generic injectables to garner a highly lucrative market share By container, prefilled syringes to experience maximum sales, fueled by growing demand for precision medicine Oncology biosimilars development gaining traction, infectious disease treatment injectables experiencing similar incline Deepening presence of prominent pharmaceutical giants widening US growth prospects Broad savings margins of nearly 90% to uplift generic injectables growth prospects across the UK Germany and France to experience credible growth in the cardiology generic injectables domain India to be the most lucrative global market, attributed to its apex position in generic drugs production Generic Injectables Market- Prominent Drivers Growing demand for inexpensive alternatives to branded injectables is spurring generic injectables market growth An expanding orphan drugs landscape to bolster future development projects for new generic injectables Manufacturers are touting enhanced generic injectables production, attributed to their potential in yielding considerable cost savings Generic Injectables Market- Key Restraints Small-scale injectable manufacturers are experiencing expansion challenges, owing to their limited capacity to source expensive raw material Thinning profit margins due to reduced drug prices have shrunk revenue pools, restraining growth Discover more about the generic injectables market with 88 figures and 106 data tables, along with the table of contents. You will also find detailed market segmentation on Competitive Landscape Prominent generic injectables manufacturers profiled by Fact.MR include Pfizer Inc., Novartis AG (Sandoz International GmbH), Baxter, Fresenius SE & Co., KGaA, Mylan NV, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Lupin Ltd., Sanofi and Biocon. Deployment of biosimilars forms the core marketing strategy of a majority of the aforementioned market players. In January 2020, Pfizer Inc. introduced three new oncology biosimilars: Zirabev (bevacizumab-bvzr), Ruxience (rituximab-pvvr) and Trazimera (trastuzumab- qyyp) across the United States. With these biosimilar launches, Pfizer became a debutant in the monoclonal antibody oncology treatment domain. Furthermore, in May 2020, the US FDA approved for review Fresenius Kabi’s Biologics License Application (BLA) for its MSB11455 pegfilgrastim biosimilar candidate for Neulasta®. This acceptance of review has provided oncologists with enhanced scope for improving cancer care across the country. Get Customization on this Report for Specific Research Solution More Valuable Insights on the Generic Injectables Market The research study on the global generic injectables market by Fact.MR incorporates an unbiased assessment of key factors and trends responsible for shaping the landscape of the global generic injectables market. Market statistics have been presented on the basis of Product (Large-molecule Injectables and Small-molecule Injectables), Container (Vials, Ampoules, Premixes, Prefilled Syringes and Others), Application (Oncology, Infectious diseases, Cardiology, Diabetes, Immunology and Others) and Route of Administration (Intravenous, Intramuscular, Subcutaneous and Others) across five major regions. Explore Fact.MR’s Coverage on the Healthcare Domain Earwax Removal Aid Market: Fact.MR’s study on the global earwax removal aid market provides detailed assessment on the key market dynamics, including drivers, trends, opportunities, restraints, and detailed information about the earwax removal aid market structure. Surgical Sutures Market: Fact.MR’s exclusive coverage on the surgical sutures market incorporates the latest and future trends shaping growth prospects across key segments and geographical locations. The report features unique and salient factors that will have a significant impact on the development of the surgical sutures market during the forecast period. Niacin and Niacinamide Market: A detailed assessment of niacin and niacinamide value chain analysis, business execution, and supply chain analysis across regional markets have been covered in Fact.MR’s exclusive coverage on the subject. Statistics about prominent segments across key geographies have also been included in this report. About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner. Contact: Sudip Saha US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583